(Q35618911)

9 August 2017

1 reference

title

Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease (English)

1 reference

9 August 2017

0 references

Hillel Grossman

1

1 reference

9 August 2017

1 November 2003

1 reference

9 August 2017

1 reference

9 August 2017

8

1 reference

9 August 2017

11

1 reference

9 August 2017

815-823

1 reference

Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization

9 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Amyloidogenic determinant as a substrate recognition motif of insulin-degrading enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Clearing the brain's amyloid cobwebs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Reanalysis of the first case of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Insulin and Alzheimer's disease: an amyloid connection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Neuroscience. Insulin insults may spur Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Glycation and microglial reaction in lesions of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Hippocampal formation glucose metabolism and volume losses in MCI and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Insulin increases CSF Abeta42 levels in normal older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Does insulin dysfunction play a role in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Role of brain insulin receptor in control of body weight and reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Familial patterns of risk in very late-onset Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Memory improvement following induced hyperinsulinemia in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Diabetes mellitus and the risk of dementia: The Rotterdam Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Association of diabetes mellitus and dementia: the Rotterdam Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

The risk of dementia among persons with diabetes mellitus: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Diabetes and dementia in long-term care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Low blood pressure and blood glucose levels in Alzheimer's disease. Evidence for a hypometabolic disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Analysis of familial and individual risk factors among patients with ischemic vascular dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Are Alzheimer patients healthier?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Insulin receptors and insulin action in the brain: review and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Demonstrating the case that AD is a vascular disease: epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Susceptibility locus for Alzheimer's disease on chromosome 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Vascular dementia, a new beginning: shifting focus from clinical phenotype to ischemic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Regulation of multicatalytic enzyme activity by insulin and the insulin-degrading enzyme

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Has familial aggregation in Alzheimer's disease been overestimated?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Advanced glycation end products contribute to amyloidosis in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Brain insulin: regulation, mechanisms of action and functions

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Evidence for genetic linkage of Alzheimer's disease to chromosome 10q

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Advanced glycation endproducts in ageing and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Diabetes and change in cognitive function

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900019258

7 January 2021

10.1017/S1092852900019258

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14702004